• 
• 
• 
• 
• 
• 

Research and Clinical Interests

Dr. Gorny is studying the humoral immune response against HIV-1 by generating human monoclonal antibodies (mAbs) that neutralize HIV-1 primary isolates. These mAbs are used to characterize viral antigens that may be used for vaccine development. He is also investigating immunoglobulin gene usage for anti-HIV-1 human mAbs and analyzing the correlation between preferentially used genes and mAb function, particularly with respect to their neutralizing activity.

Selected Publications

Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nadas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol. 2006;80(14):6865-72. Cited in Pubmed; PMID 16809292.

Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005;79(8):5232-7.

Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses. 2004;20(11):1254-8. Cited in Pubmed; PMID 15588347.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol. 2004;78(5):2394-404. Cited in Pubmed; PMID 14963135.

Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 2004;12(2):193-204. Cited in Pubmed; PMID 14962380.

Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol. 2002;76(18):9035-45. Cited in Pubmed; PMID 12186887.

Gorny MK, VanCott TC, Williams C, Revesz K, Zolla-Pazner S. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Virology. 2000;267(2):220-8. Cited in Pubmed; PMID 10662617.

Gorny MK, Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol. 2000;74(13):6186-92. Cited in Pubmed; PMID 10846104.

Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, Balfe P, Hioe C, Brodine S, Burda S, Zolla-Pazner S. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res Hum Retroviruses. 1998;14(3):213-21. Cited in Pubmed; PMID 9491911.

Bandres JC, Wang QF, O'Leary J, Baleaux F, Amara A, Hoxie JA, Zolla-Pazner S, Gorny MK. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4 [ABBREVIATED]. J Virol. 1998;72(3):2500-4. Cited in Pubmed; PMID 9499113.

Gorny MK, VanCott TC, Hioe C, Israel ZR, Michael NL, Conley AJ, Williams C, Kessler JA 2nd, Chigurupati P, Burda S, Zolla-Pazner S. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol. 1997;159(10):5114-22. Cited in Pubmed; PMID 9366441.

Gorny MK, Keler T, Burda S, Williams C, Gabriel JL, Mitchell WM, Deo YM, Zolla-Pazner S. Functional studies of bispecific antibodies directed against HIV-1 and the Fc gamma I receptor type I. Antibiot Chemother. 1996;48:173-83. Cited in Pubmed; PMID 8726522.

Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol. 1994;68(12):8312-20. Cited in Pubmed; PMID 7525987.

Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol. 1993;150(2):635-43. Cited in Pubmed; PMID 7678279.

Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol. 1992;66(12):7538-42. Cited in Pubmed; PMID 1433529.

Selected Books

Gorny MK, Zolla-Pazner S. Human monoclonal antibodies that neutralize HIV-1. In: Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, Watkins DI, editors. HIV Immunology and HIV/SIV Vaccine Databases 2003. Los Alamos, N.M.: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2004. pp. 37-51.

Gorny MK. Production of human monoclonal antibodies via fusion of Epstein-Barr virus-transformed lymphocytes with heteromyeloma. In: Celis J, editor. Cell Biology: A Laboratory Handbook. San Diego: Academic Press; 1994. pp. 276-81.

Vitetta ES, Till MA, Ghetie V, Uhr JW, Patton JS, Gregory T, Patzer EJ, Porter JP, Capon DJ, Gorny MK, Zolla-Pazner S. Immunoconjugates containing ricin A chain can kill cell lines of HIV infected T cells and monocytes. In: Baldwin RW, Vyers VS, Mann RD, editors. Monoclonal Antibodies and Immunoconjugates. Park Ridge, NJ: Parthenon Publishing Group; 1990. pp. 79-94.

Gorny MK, Pinter A, Zolla-Pazner S. Specific immunity to HIV and other retroviral infections. In: Rotterdam H et al., editor. Progress in AIDS Pathology. New York: Field & Wood Publ.; 1989. pp. 181-199.

Organizational Associations

American Association of Immunologists; American Association for the Advancement of Science